Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 49 | 2,094 | 46% |
| 2020 | 31 | 1,590 | 48% |
| 2021 | 38 |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 50% of the cases CMS names in New York; 22 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 23 | 1,666−3.1%/yr | −3.1%/yr | 1.2 | 0% | 1,760 in 2030+0.9%/yr |
| New Jersey | 26 | 1,073 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 109 | 13,452−13%/yr | −13%/yr | 7.71.7× | 80% | 12,500 in 2030−1.2%/yr |
| Peripheral arterial intervention |
Carotid revascularization in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
| 2024 |
| 1,508 |
| 57% |
| 2025 est. | ≈ 1,460 | – |
| 2026 est. | ≈ 1,480 | – |
| 1,648 |
| 51% |
| 2022 | 32 | 1,685 | 53% |
| 2023 | 37 | 1,609 | 55% |
| 2024 | 32 | 1,508 | 57% |
| 2025 from claims | – | 1,464 1,344–1,549 | 58% |
| 2026 forecast | – | 1,477 1,300–1,705 | 58% |
| 2027 forecast | – | 1,485 1,269–1,769 | 59% |
| 2028 forecast | – | 1,492 1,245–1,827 | 59% |
| 2029 forecast | – | 1,499 1,224–1,879 | 60% |
| 2030 forecast | – | 1,505 1,206–1,929 | 60% |
In 2025, 100% inpatient hospital.
| −1.9%/yr |
| 1.0 |
| 0% |
| 1,090 in 2030+0.2%/yr |
| Massachusetts | 18 | 984−3.3%/yr | −3.3%/yr | 1.0 | 0% | 1,170 in 2030+2.9%/yr |
| Connecticut | 1 | 337−3.8%/yr | −3.8%/yr | 1.0 | 0% | 320 in 2030−1%/yr |
| New Hampshire | 4 | 267−3.3%/yr | −3.3%/yr | 1.2 | 0% | 360 in 2030+5.1%/yr |
| Maine | 0 | 161−5.5%/yr | −5.5%/yr | 1.0 | 0% | 670 in 2030+27%/yr |
| Rhode Island | 3 | 142+2.9%/yr | +2.9%/yr | 1.5 | 0% | 70 in 2030−11%/yr |
| 97 |
| 12,468−0.1%/yr |
| −0.1%/yr |
| 6.51.5× |
| 60% |
| 16,300 in 2030+4.6%/yr |
| Superficial venous ablation | 132 | 8,630−5.2%/yr | −5.2%/yr | 4.51.6× | 97% | 9,880 in 2030+2.3%/yr |
| Thrombectomy, IVC filters & venous stents | 24 | 2,696−2.3%/yr | −2.3%/yr | 1.51.2× | 17% | 3,720 in 2030+5.5%/yr |
| Aortic endografts (EVAR/TEVAR) | 7 | 818−5.7%/yr | −5.7%/yr | 0.51.1× | 0% | 860 in 2030+0.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 5,492 carotid endarterectomy and stenting stays at 55 hospitals in 2024, against the Medicare-only figures above. The most commercial of the busy ones is GARNET HEALTH MEDICAL CENTER (34% commercial): where commercial rates leave the most room for a premium product.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| NYU LANGONE HOSPITALS NEW YORK | 423 | 69% | 21% |
| KALEIDA HEALTH BUFFALO | 340 | 74% | 14% |
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 271 | 63% | 25% |
| MOUNT SINAI HOSPITAL NEW YORK | 245 | 71% | 20% |
| ROCHESTER GENERAL HOSPITAL ROCHESTER | 227 | 83% | 11% |
| ST JOSEPH'S HOSPITAL HEALTH CENTER SYRACUSE | 224 | 84% | 10% |
| STRONG MEMORIAL HOSPITAL ROCHESTER | 210 | 71% | 18% |
| ALBANY MEDICAL CENTER HOSPITAL ALBANY | 208 | 52% | — |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (Carotid endarterectomy and stenting). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.
Boston Scientific leads with 49% of company spending on these surgeons in 2025, −16 pts on 2024.
In 2025, 8 companies reported engagement with New York’s surgeons worth $208K in consulting, speaking, meals and travel tied to these products, about $6,499 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.